Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment - PRELUDE Study

NCT07460206 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT07460206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07460206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment - PRELUDE Study
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2031
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ccrcc